Review Article
A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges
Table 3
Few marketed preparations for treatment of keratoconjunctivitis sicca.
| Manufacturer | Brand | Content | Delivery system and indication |
| Allergan, Inc. | Restasis (by prescription) | Cyclosporin A 0.05% w/v | Oil-based emulsion DED treatment | Refresh Optive | Contains 2 osmolytes L-carnitine and erythritol and CMC sodium 5 mg | Eye drops |
| Sun Pharma Ind. Ltd. | Cyclomune | Cyclosporin A 0.05% w/v | Drops DED treatment |
| Bausch & Lomb Inc. | Lotemax | Loteprednol etabonate 0.5% | Suspension drops (steroid) for short-term therapy |
| Novartis Ltd. | Voltaren | Diclofenac sodium ophthalmic solution) 0.1% | Drops |
| FDC Ltd. | ZO-D eye drops | Ofloxacin and dexamethasone | Drops |
| Allergan India Pvt. Ltd. | Acular LS | Ketorolac tromethamine 0.4% | Drops | Toba Toba DM Toba F | Tobramycin USP Tobramycin and dexamethasone Tobramycin and fluorometholone | Drops |
| Ocusoft, Inc. | Retaine MGD | Cationic O/W emulsion technology | Hypotonic emulsion provides lubrication |
| Otsuka Pharmaceuticals | Mucosta ophthalmic suspension UD2% | Rebamipide | Marketed in China, Japan, Indonesia, Malaysia, and Thailand |
| Advanced Vision Research | Thera tears nutrition | Omega 3 fatty acids | Gel capsules |
|
|